Martin Rees: We Are Living Through A Political And Scientific Transformation
Lord Martin Rees is an astrophysicist and the former master of Trinity College, Cambridge. He sat down with The WorldPost for a wide-ranging interview, which has been edited for clarity and brevity.
Alexander Görlach: Out of all great transformations we are going through, from climate change to artificial intelligence to gene editing, what are the most consequential we are about to witness?
Martin Rees: It depends on what time scale we are thinking about. In the next 10 or 20 years, I would say it’s the rapid development in biotechnology. We are already seeing that it’s becoming easier to modify the ...
Source: Science - The Huffington Post - February 21, 2017 Category: Science Source Type: news
From Interventional Radiologist to Medtech CEO: Interview with Dr. Bob Smouse, Founder of BrightWater Medical
Welcome to the Medsider interview series, a regular feature at MassDevice. All interviews are conducted by Scott Nelson, Founder of Medsider and Group Director for WCG. We hope you enjoy them!
Dr. Bob Smouse has over 20 years of experience in interventional radiology, endovascular surgery and clinical research. In addition to acting as CEO and CMO of BrightWater Medical and teaching at the University of Illinois College of Medicine, he provides interventional medical services to local hospitals through Central Illinois Radiology Associates.
Dr. Smouse is a medical consultant and scientific advisory board member for a ho...
Source: Mass Device - February 10, 2017 Category: Medical Equipment Authors: Danielle Kirsh Tags: Blog medsider Smouse Source Type: news
Slow Medicine: Eyeing the Evidence for Laser Surgery
(MedPage Today) -- Scant data on this ubiquitous procedure (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - February 9, 2017 Category: Primary Care Source Type: news
Laser May Be Best Skin Primer for Photodynamic Therapy Laser May Be Best Skin Primer for Photodynamic Therapy
Laser pretreatment seems the most effective way to enhance methyl aminolevulinate hydrochloride-induced protoporphyrin IX (PPIX) formation in photodynamic therapy (PDT), according to Danish researchers.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - February 8, 2017 Category: Surgery Tags: Plastic Surgery & Aesthetic Medicine News Source Type: news
Are you seeing ghosts? Get yourself to an optician NOT an exorcist, leading expert warns
Dr David Allamby, a laser eye surgeon at London's Focus Clinic, says hallucinations can be caused by Charles Bonnet syndrome that affects people who have experienced vision loss. (Source: the Mail online | Health)
Source: the Mail online | Health - January 13, 2017 Category: Consumer Health News Source Type: news
Lessons Learned Building Acclarent from Scratch: Interview with Bill Facteau, President and CEO of Earlens
Bill Facteau, President and CEO of Earlens
Welcome to the Medsider interview series, a regular feature at MassDevice. All interviews are conducted by Scott Nelson, Founder of Medsider and Group Director for WCG. We hope you enjoy them!
Bill Facteau joined Earlens Corporation as Chairman, President, and CEO in November of 2013. Most recently, he was the Vice Chairman of ExploraMed as well as an Entrepreneur in Residence at New Enterprise Associates. Previously, Bill was at Johnson & Johnson from early 2010 through early 2012 as Worldwide President of their ENT Division. Facteau joined Johnson & Johnson via the $8...
Source: Mass Device - January 10, 2017 Category: Medical Equipment Authors: Scott Nelson Tags: Blog EarLens medsider Source Type: news
Ivantis raises $25m in Series C to support Hydrus microstent
Ivantis said today it raised $25 million in a Series C round of financing to support its Hydrus microstent device designed for treating glaucoma.
The round was led by newly invested RA Capital Management and joined by new investor Mérieux Développement and existing investors.
Money raised will extend Irvine, Calif.-based Ivantis’ runway into 2020 and help support US commercialization of the Hydrus Microstent upon receiving FDA approval, which the company expects to receive in 2018.
“We are pleased to complete this financing, which we expect will fund Ivantis well beyond the Hydrus microstent launch, and at th...
Source: Mass Device - January 9, 2017 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Optical/Ophthalmic Ivantis Source Type: news
What--and Why--the Neonatologist Should Know About Twin-To-Twin Transfusion Syndrome
Twin-to-twin transfusion syndrome results from unbalanced vascular anastomoses in monochorionic twin gestations. This condition, affecting 2,500 pregnancies each year in the United States, is most commonly identified with ultrasonography on the basis of unequal amniotic fluid volumes in a monochorionic, diamniotic pregnancy. Hemodynamic alterations in the syndrome lead to oligohydramnios, intrauterine growth restriction, and frequently, anemia in the "donor" twin while the "recipient" has polyhydramnios and polycythemia. In severe cases, both twins are at risk of developing hydrops fetalis and death. The Quintero staging s...
Source: NeoReviews recent issues - January 1, 2017 Category: Pediatrics Authors: Bliss, J. M., Carr, S. R., De Paepe, M. E., Luks, F. I. Tags: Pediatric Drug Labeling Update Articles Source Type: news
Better tool to help assess LASIK Patients
By: Malvina Eydelman, MD
LASIK (laser-assisted in situ keratomileusis) eye surgery is an alternative for patients who need glasses or contacts to see well. Some 600,000 to 800,000 patients undergo LASIK in the U.S. each year, and a very high number of those patients are satisfied with their surgical outcomes.
However, some patients develop unwanted visual symptoms following surgery, symptoms that can have a significant impact on their daily lives. Patients who see starbursts, glare, ghosting, or halos—or those who experience severe dry eye—may have their daily lives change in negative ways.
While there are risks with a...
Source: Mass Device - December 21, 2016 Category: Medical Equipment Authors: MassDevice Tags: Blog FDA Source Type: news
MassDevice.com +5 | The top 5 medtech stories for December 20, 2016
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Get this in your inbox everyday by subscribing to our newsletters.
5. 21st Century Cures Act adds Hatch-Waxman rule to drug-device combos
Section 3038 of the 21st Century Cures Act applies Hatch-Waxman rules to certain drug-device combination products, addressing the regulatory pathway for device...
Source: Mass Device - December 20, 2016 Category: Medical Equipment Authors: MassDevice Tags: News Well Plus 5 Source Type: news
Laser-activated drug offers new hope for prostate cancer treatment
A new laser-based treatment for prostate cancer has shown promise as a new therapy, without the need for surgery. (Source: CNN.com - Health)
Source: CNN.com - Health - December 20, 2016 Category: Consumer Health News Source Type: news
New laser therapy for low-risk prostate cancer shows promise
Conclusion
This large randomised controlled trial indicates that the new treatment vascular-targeted photodynamic therapy for men with low-risk prostate cancer results in a greater chance of being declared cancer-free, and slows the progress of the disease.
The treatment also reduced the number of men who needed to have further surgery or radiotherapy to 6%, compared with 29% in the active surveillance group.
This is a well-designed trial conducted in several countries that followed men for a reasonably long period of time.
It also analysed all men included in the study, regardless of whether they completed treatment or ...
Source: NHS News Feed - December 20, 2016 Category: Consumer Health News Tags: Cancer Older people Source Type: news
Prostate cancer laser treatment could be a game changer for men
A drug that can kill cancerous cells without the side-effects of radical surgery is causing massive excitement for good reasonProstate has long been the Cinderella of cancers, lagging behind others – in particular breast cancer – when it comes to diagnosis, treatment and the funding that goes into research.But scientists at University College London have made what they believe is a real breakthrough using a drug derived from bacteria found at the bottom of the sea,injected into the bloodstream and activated in the prostate by laser beams. There is also massive excitement from from patients, who have been calling UCL ev...
Source: Guardian Unlimited Science - December 20, 2016 Category: Science Authors: Sarah Boseley Tags: Cancer Cancer research Health Medical research Science Society Health policy Politics Public services policy & wellbeing Life and style UK news Source Type: news
Prostate cancer laser treatment could be a gamechanger for men
A drug that can kill cancerous cells without the side-effects of radical surgery is causing massive excitement for good reasonProstate has long been the Cinderella of cancers, lagging behind others – in particular breast cancer – when it comes to diagnosis, treatment and the funding that goes into research.But scientists at University College London have made what they believe is a real breakthrough using a drug derived from bacteria found at the bottom of the sea,injected into the bloodstream and activated in the prostate by laser beams. There is also massive excitement from patients, who have been calling UCL ever si...
Source: Guardian Unlimited Science - December 20, 2016 Category: Science Authors: Sarah Boseley Tags: Cancer Cancer research Health Medical research Science Society Health policy Politics Public services policy & wellbeing Life and style UK news Source Type: news
Prostate cancer laser treatment 'truly transformative'
Surgeons describe a new treatment for early stage prostate cancer as "truly transformative". (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - December 20, 2016 Category: Consumer Health News Source Type: news
